Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study. Issue 5 (May 2018)

• Record Type: Journal Article
• Authors: Li, Qing; Ding, Yan; Zhang, Xu-Yin; Feng, Wei-Wei; Hua, Ke-Qin
• Is Part Of: Journal of international medical research. Volume 46:Issue 5(2018)
• Page Start: 1855
• Page End: 1865
• Publication Date: 2018-05
• Subjects: Adenomyosis -- gonadotropin-releasing hormone analogues -- half-dose -- efficacy -- adverse effect -- Mirena; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060517752997
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To provide novel insights into the clinical treatment of adenomyosis. Methods: Two hundred patients with adenomyosis were enrolled in this prospective, nonrandomized, parallel-controlled study with a 1-year follow-up in our hospital. Group 1 was treated with 3.75 mg leuprorelin acetate (LA) (n = 40), Group 2 was treated with 1.88 mg LA (n = 40), Group 3 underwent Mirena implantation (n = 40), Group 4 underwent Mirena implantation after treatment with 3.75 mg LA (n = 40), Group 5 underwent Mirena implantation after treatment with 1.88 mg LA (n = 20), and Group 6 received San-Jie-Zhen-Tong capsules alone (n = 20). Uterine volume, pain, cancer antigen 125 level, ovary function, adverse effects, and Mirena expulsion were evaluated. Results: The uterine volume and pain scores were lower in the groups treated with 1.88 than 3.75 mg LA, but the lower dose was associated with significantly fewer hot flashes and sweating. The 1-year Mirena expulsion rate was higher in Group 3 than in Groups 4 and 5 (10.00% vs. 3.33%, respectively). Costs were significantly higher in Groups 1 and 4 than in Groups 2 and 5. Conclusion: Administration of 1.88 mg LA may be an alternative therapy for Asian patients with adenomyosis. The combination of LA and Mirena could enhance the therapeutic effect. Registration number: ChiCTR-IPR-15005971